Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
First in the Class of Sustained Follicle Stimulants Would Reduce the Number of Treatment Injections for Patients WHITEHOUSE STATION, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc...
CHICAGO, Sept. 28 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for MRK, URBN, GG, IP and ADM. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
Lawsuit settles claims regarding efficacy and safety of popular prescription drugs. BOSTON, Aug. 5 /PRNewswire/ -- Attorneys representing consumers and third-party payors today announced a...
CHICAGO, July 20 /PRNewswire/ -- Seven Summits Strategic Investments releases its Stocks To Watch Guide. The Seven Summits Strategic Investments Stocks To Watch Guide (go to:...
PGA TOUR golfer Tom Lehman tees-off Triple Threat Challenge about heart disease and cholesterol education ORLANDO, Fla., Nov. 6 /PRNewswire-FirstCall/ -- More Americans are likely to know their...
NEWPORT BEACH, Calif., Aug. 31 /PRNewswire/ -- In response to Merck's statement Wednesday that the company would seek a new trial on "all liability issues," Mark P. Robinson, Jr., lead plaintiff...
NEWPORT BEACH, Calif., Aug. 17 /PRNewswire/ -- Today a unanimous eight-man jury in New Orleans rendered a $51,000,000 verdict against Merck & Co., Inc., and its drug Vioxx. This lawsuit arises...
New Nature study shows potential of 'entry inhibitor' compounds as HIV prevention tool NEW YORK, Oct. 31 /PRNewswire/ -- In a first-of-its-kind joint announcement, two of the world's leading...
Viles & Beckman, P.A. File Vioxx Class Action in Fort Myers FORT MYERS, Fla., Oct. 26 /PRNewswire/ -- Viles & Beckman, P.A. filed a class action lawsuit yesterday challenging Merck & Co., Inc...
Johnson & Johnson to Acquire Merck & Co., Inc.'s Interest in European Consumer Pharmaceuticals Joint Venture NEW BRUNSWICK, N.J. and WHITEHOUSE STATION, N.J., Feb. 27 /PRNewswire- FirstCall/...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
